Boston Scientific Corporation invested $1.5 billion [1] for a roughly 34% [1] equity stake in Georgia-based startup MiRus LLC on Monday, May 18, 2026 [1].
The move signals a strategic effort by the U.S. medical device maker to re-enter the heart-valve segment. By targeting the aortic stenosis market, Boston Scientific aims to capture a rapidly growing sector of cardiovascular care [3].
As part of the agreement, Boston Scientific obtained an exclusive option to acquire the investigational transcatheter aortic valve replacement (TAVR) heart-valve business from MiRus [1]. This TAVR technology is designed to treat aortic stenosis, a condition where the heart's aortic valve narrows and restricts blood flow [3].
MiRus LLC is a privately held company based in Georgia, U.S. [2]. The investment allows Boston Scientific to align itself with the startup's development of next-generation valve therapies, while maintaining a flexible path toward a full acquisition of the business unit [2].
Industry analysts said that the $1.5 billion [1] commitment reflects the high stakes of the heart-valve market. The TAVR procedure has become a primary method for treating valve disease without the need for open-heart surgery, making it a high-growth area for medical technology firms [3].
This investment represents a significant capital commitment for the company as it seeks to diversify its cardiovascular portfolio. The deal provides Boston Scientific with a foothold in a specialized market that has seen increasing demand as patient populations age [3].
“Boston Scientific invested $1.5 billion for a roughly 34% equity stake in Georgia-based startup MiRus LLC.”
This deal highlights a shift in the medical device landscape where established giants use equity stakes and purchase options to mitigate the risk of developing unproven, investigational technologies. By securing an option for the TAVR business rather than an immediate full buyout, Boston Scientific can monitor the clinical success of the MiRus valve before committing to a total acquisition, while effectively blocking competitors from accessing the same technology.
